1369405-80-0

Upstream product

• 100-39-0 benzyl bromide 
• 61893-74-1 allyl 2,3,6-tri-O-benzyl-α-D-galactopyranoside 
• 20746-71-8 (4aR,6S,7R,8S,8aS)-6-(allyloxy)-7,8-bis(benzyloxy)-2-phenylhexahydropyrano[3,2-d][1,3]dioxine 
• 1125-88-8 benzaldehyde dimethyl acetal 
• 48149-72-0 (2S,3R,4S,5R,6R)-2-Allyloxy-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol 
• 1369405-70-8 (2R,3R)-3-(benzyloxy)-1-((tert-butyldimethylsilyl)oxy)-4,4-difluorohex-5-en-2-ol 
• 1369405-79-7 (2S,3R,5R)-2,3,6-tris(benzyloxy)-4,4-difluorohexane-1,5-diol 
• 1369405-77-5 (2R,4R,5S)-1,4,5-tris(benzyloxy)-6-((tert-butyldimethylsilyl)oxy)-3,3-difluorohexan-2-ol 
• 1369405-76-4 C₂₆H₃₈F₂O₅Si 
• 1369405-75-3 (((2S,3R)-2,3-bis(benzyloxy)-4,4-difluorohex-5-en-1-yl)oxy)(tert-butyl)dimethylsilane 
• 1369405-74-2 (2S,3R)-3-(benzyloxy)-1-((tert-butyldimethylsilyl)oxy)-4,4-difluorohex-5-en-2-ol 
• 1369405-73-1 C₁₃H₁₆F₂O₃ 
• 1369405-72-0 (2S,3R)-3-(benzyloxy)-4,4-difluorohex-5-ene-1,2-diyl diacetate 
• 1369405-71-9 (S)-2-((R)-1-(benzyloxy)-2,2-difluorobut-3-en-1-yl)oxirane 

Downstream Products

• 1369406-03-0 C₄₂H₄₁ClF₂O₆ 
• 1181680-69-2 (2R,4R,5S,6S)-4,5-bis(benzyloxy)-2-((benzyloxy)methyl)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)-3,3-difluorotetrahydro-2H-pyran 
• 1181680-71-6 (2S,3R,4R,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-5,5-difluoro-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diol 
• 1369405-81-1 (2R,4R,5S,6S)-4,5-bis(benzyloxy)-2-((benzyloxy)methyl)-6-(4-chloro-3-(4-isopropoxybenzyl)phenyl)-3,3-difluorotetrahydro-2H-pyran 
• 1369405-82-2 (2R,4R,5S,6S)-4,5-bis(benzyloxy)-2-((benzyloxy)methyl)-6-(4-chloro-3-(4-propoxybenzyl)phenyl)-3,3-difluorotetrahydro-2H-pyran 
• 1369405-83-3 (2R,4R,5S,6S)-4,5-bis(benzyloxy)-2-((benzyloxy)methyl)-6-(4-chloro-3-(4-methoxybenzyl)phenyl)-3,3-difluorotetrahydro-2H-pyran 
• 1181680-59-0 (2R,4R,5S,6S)-4,5-bis(benzyloxy)-2-((benzyloxy)methyl)-6-(4-chloro-3-(4-ethylbenzyl)phenyl)-3,3-difluorotetrahydro-2H-pyran 
• 1369405-84-4 (2R,4R,5S,6S)-4,5-bis(benzyloxy)-2-((benzyloxy)methyl)-6-(4-chloro-3-(4-methylbenzyl)phenyl)-3,3-difluorotetrahydro-2H-pyran 
• 1369405-85-5 (2R,4R,5S,6S)-4,5-bis(benzyloxy)-2-((benzyloxy)methyl)-6-(3-(4-ethoxybenzyl)-4-methylphenyl)-3,3-difluorotetrahydro-2H-pyran 
• 1369405-86-6 (2R,4R,5S,6S)-4,5-bis(benzyloxy)-2-((benzyloxy)methyl)-6-(3-(4-isopropoxybenzyl)-4-methylphenyl)-3,3-difluorotetrahydro-2H-pyran 
• 1181681-87-7 (2S,3R,4R,6R)-2-(4-chloro-3-(4-isopropoxybenzyl)phenyl)-5,5-difluoro-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diol 
• 1369405-54-8 (2S,3R,4R,6R)-2-(4-chloro-3-(4-propoxybenzyl)phenyl)-5,5-difluoro-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diol 
• 1181681-54-8 (2S,3R,4R,6R)-2-(4-chloro-3-(4-methoxybenzyl)phenyl)-5,5-difluoro-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diol 
• 1181680-61-4 (2S,3R,4R,6R)-2-(4-chloro-3-(4-ethylbenzyl)phenyl)-5,5-difluoro-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diol 

Relevant academic research and scientific papers

5,5-Difluoro- and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors

(2S,3R,4R,5S,6R)-2-Aryl-5,5-difluoro-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diols and (2S,3R,4R,5S,6R)-2-aryl-5-fluoro-5-methyl-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diols were discovered as dual inhibitors of sodium glucose co-transporter proteins (

5,5-DIFLUORO- AND 5-FLUORO-5-METHYL-C-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS

The present invention is directed to 5,5-difluoro- and 5-fluoro-5-methyl-C-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity.

BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS

The present invention is directed to benzocyclobutane derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity. More particularly, the compounds of the present invention are useful in the treatment of for example, Type II diabetes mellitus, Syndrome X, and complications and symptoms associated with said disorders.

Synthesis and biological evaluation of SGLT2 inhibitors: Gem-difluoromethylenated Dapagliflozin analogs

Dapagliflozin is currently the most advanced SGLT2 inhibitor, which has been used in Phase III clinical trials for treatment of diabetes. Here we describe the design and synthesis of Dapagliflozin analogs modified with gem-difluoromethylene group. Their b